NCT06364176

Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.

Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 42 (estimated)
• Sponsor: University of Kansas Medical Center · Academic / Other
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to test use of losartan in those with cystic fibrosis (CF) on modulator therapy. The main question it aims to answer is if treatment with losartan improves response of the CF transmembrane conductance regulator (CFTR) channel to modulator therapy. Participants will be asked take losartan or placebo for twelve weeks and will have changes in sweat chloride levels measured as a marker of CFTR function.

Detailed description

This is a randomized, placebo-controlled, parallel group clinical trial in those those with CF on elexacaftor/tezacaftor/ivacaftor to determine if treatment with losartan improves response to modulator therapy using sweat chloride as an marker of CFTR function.

Conditions

• Cystic Fibrosis

Interventions

Type	Name	Description
DRUG	Losartan	Treatment with losartan through week 12
DRUG	Placebo	Treatment with placebo through week 12

Timeline

• Start date: 2024-06-03
• Primary completion: 2027-05-01
• Completion: 2027-10-01
• First posted: 2024-04-15
• Last updated: 2025-05-02

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study